SUBSTANCE ABUSE TREATMENT Market Size, Share & Industry Analysis, By Treatment (Alcohol Addiction Treatment, Tobacco/Nicotine Addiction Treatment, Opioid Addiction Treatment, Other), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels ) Others and Regional Forecast, 2024-2032

In November 2017, Indivior PLC received approval by the U.S. Food and Drug Administration for a monthly injection of buprenorphine to treat opioid addiction. Substance abuse is defined as the harmful use of psychoactive substances, comprising illegal drugs and alcohol. The use of a psychoactive substance can cause dependence syndrome - a combination of physiological problems, cognitive, behavioral, and that develop after steady consumption of the substance. The other symptoms include difficulty in controlling the use, increased tolerance of the substance, and others. It has been projected that worldwide approximately 62 million people had a drug consumption disorder in 2017, one-third female (20 million) and two-thirds were male (40 million). In November 2017, the Food and Drug Administration (FDA) approved an electronic stimulation device called NSS-2 Bridge, used to reduce opioid withdrawal symptoms.

The global substance abuse treatment market growth is being driven by the increasing incidence & prevalence of illicit drug intake in adults and excessive consumption of tobacco & alcohol. Various awareness campaigns being introduced by the regional non-profit organizations and national governments through advertisements on television, newspapers, magazines, and others have increased the awareness about substance abuse treatment. This is expected to further augment the number of patients undergoing substance abuse treatment, and fuel the growth of the market during the forecast period.

The factor that is expected to inhibit the growth of the market is the lack of awareness among the general and patient population, especially in developing countries about substance abuse treatments available and lack of treatment endurance and compliance among the patients.

Market Segmentation:

By treatment, the market is segmented into alcohol addiction treatment, tobacco/nicotine addiction treatment, opioid addiction treatment,   and others. Based on distribution channels, the substance abuse treatment market is segmented into hospital pharmacies, retail pharmacies, and other distribution channels.

From a geographical standpoint, the market is categorized into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

Key Players Covered:

The major companies covered in the global substance abuse market are Cipla Ltd., Alkermes plc, Allergan plc, Pfizer Inc., GlaxoSmithKline plc, Orexo AB, Mallinckrodt, Purdue Pharma L.P, Reckitt Benckiser Group plc, and Intas Pharmaceuticals Ltd., and other players.

At present, nicotine addiction treatment considered to account for the highest market share. This is due to the highest sale of nicotine gum in the market, this segment is predicted to continue the dominance in the forecast period.

Key Insights

• Prevalence of substance abuse (key countries/ key regions)


• Advancements in research & development of treatment options


• Overview of advances in novel therapeutics


• Introduction of new products (by major players)

Regional Analysis:

The global substance abuse treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The substance abuse treatment market is anticipated to expand in North America during the forecast years owing to the higher prevalence of drug addiction. For instance, according to a study conducted by Addiction Center, a US-based non-profit organization, an estimated 700,000 people lost their lives due to drug abuse in the US during the past two decades. Moreover, according to the study, deaths caused due to drug abuse in the US have been tripled since 2000.

This, combined with initiatives taken by the government in order to reduce drug abuse are likely to offer significant opportunities for the growth of the North America substance abuse treatment market during the forecast period. In Europe, increasing awareness about consequences caused by drug abuse in countries such as Germany, UK, and France is projected to boost the growth of the Europe substance abuse treatment market by 2026.  Asia Pacific expected to register a comparatively higher CAGR from 2019-2026 due to a higher prevalence of drug abuse, coupled with the implementation of strategic programs to curb addiction in countries such as China & India. In Latin America and Middle East & Africa, unmet needs for substance abuse treatment is expected to drive the market growth in these regions.

Segmentation

Substance Abuse Market Industry Developments

• In November 2018, Sandoz, a subsidiary of Novartis AG, and Pear Therapeutics, Inc., launched reSET for patients with Substance Use Disorder (SUD).


• In May 2018, US WorldMeds, LLC., received the U.S. Food and Drug Administration approval for Lucemyra (lofexidine hydrochloride), the first ever non-opioid based treatment used for management of opioid withdrawal symptoms in adults.